Fezolinetant Approved for Menopause Hot Flushes: NICE Guidance

A new treatment option for women experiencing disruptive menopausal symptoms – hot flushes and night sweats – has received a positive recommendation from the National Institute for Health and Care Excellence (NICE). The guidance, issued on March 11, 2026, opens the door for fezolinetant, also known as Veoza and manufactured by Astellas Pharma, to be made available on the NHS for those for whom hormone replacement therapy (HRT) isn’t suitable. This development addresses a significant gap in care, offering a non-hormonal alternative for the roughly 500,000 women in England who could benefit.

Understanding Vasomotor Symptoms and Current Treatment Options

Menopause marks the finish of a woman’s reproductive years, and is a natural biological process. However, it’s often accompanied by a range of symptoms, with vasomotor symptoms (VMS) – hot flushes and night sweats – being among the most common and debilitating. These symptoms can significantly impact daily life, disrupting sleep, concentration, and overall wellbeing.

HRT has long been the first-line treatment for moderate to severe VMS. However, it’s not without its considerations. Some women are unable to take HRT due to medical contraindications, personal preference, or concerns about potential side effects. Until now, options for these women have been limited. As Helen Knight, director of medicines evaluation at NICE, stated, “For those who are unable to take HRT for varying reasons, options have historically been limited, and we have heard clearly from patients how difficult that can be.”

How Fezolinetant Works: A Non-Hormonal Approach

Fezolinetant represents a new class of non-hormonal treatment for VMS. Unlike HRT, which replaces declining hormones, fezolinetant works by targeting the brain’s temperature regulation system. Specifically, it blocks the nerve pathways that trigger hot flushes and night sweats. The medication is administered as a 45mg tablet taken once daily.

The British Menopause Society (BMS) has welcomed the NICE decision, emphasizing the importance of providing alternative options for women who cannot or choose not to use HRT. The BMS notes that while hormonal treatment remains appropriate for many, access to a non-hormonal medication will offer much-needed relief to others.

Evidence Supporting the NICE Recommendation

The NICE recommendation is based on clinical trial data demonstrating the efficacy and cost-effectiveness of fezolinetant. The trials showed that the drug can meaningfully reduce the frequency and severity of hot flushes and night sweats. The BMJ reports that the evidence supported the drug being cost-effective for the NHS.

However, it’s essential to note that the trials also have limitations. As with any medication, fezolinetant is not without potential side effects, which were observed in clinical trials and are detailed in the prescribing information. Common side effects include headache, diarrhea, and fatigue. Further long-term studies are needed to fully understand the long-term effects of the medication.

What This Means for Patients and Healthcare Providers

The availability of fezolinetant expands the treatment options available to women experiencing troublesome VMS. It allows clinicians to tailor treatment plans to individual patient needs and preferences, taking into account medical history, symptom severity, and personal choices.

It’s crucial to emphasize that HRT remains the first-line treatment for most women with moderate to severe VMS, given its established benefits and the variety of formulations available. Fezolinetant is intended as an alternative for those for whom HRT is not suitable.

The NICE Evaluation Process and Future Considerations

NICE’s recommendation is the result of a rigorous evaluation process. The Institute assesses the clinical and cost-effectiveness of new medicines and technologies to determine whether they should be made available on the NHS. The final draft guidance is now open for comment before final publication.

The approval of fezolinetant highlights the ongoing demand for research into menopause and the development of effective treatments. Continued surveillance of the drug’s safety and effectiveness in real-world settings will be essential. NICE’s announcement signals a commitment to improving the care and quality of life for women experiencing menopause.

Looking Ahead: Healthcare professionals are encouraged to stay updated on the latest guidance and to engage in shared decision-making with their patients to determine the most appropriate treatment approach. Women experiencing menopausal symptoms should discuss their options with a qualified clinician to receive personalized advice and care.